In 1995, Poly’s first product, Nimodipine capsule, gained Market Authorization in China.

After 2010, Poly was subsequently inspected by authorities of WHO, EU EMA, US FDA. The first product Ganciclovir was exported to Germany and Netherlands.

In 2015, the manufacturing facility in Hainan was rated as “Demonstration Factory of Intelligent Production in Pharmaceutical Industry” by Chinese government.

In 2017, Poly completed Initial Public Offering and was listed on Shenzhen Stock Exchange (300630.SZ) with approximate US$1.5 billion of market value (July 2018).
A new facility in Hangzhou started its operation.

In 2018, the third facility laid its foundation in Anqing for high-end API with designed capacity of 300 tons.